Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avibactam/aztreonam - AbbVie/AstraZeneca/Pfizer

Next Previous
Drug Profile

Avibactam/aztreonam - AbbVie/AstraZeneca/Pfizer

Alternative Names: EMBLAVEO; ATM-AVI; Aztreonam-avibactam; PF-06947387

Latest Information Update: 12 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AbbVie; AstraZeneca; Biomedical Advanced Research and Development Authority; Innovative Medicines Initiative; Pfizer
  • Class Amides; Anti-infectives; Antibacterials; Heterocyclic bicyclo compounds; Monobactams; Small molecules; Sulfates
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Gram-negative infections; Intra-abdominal infections

Most Recent Events

  • 07 Feb 2025 Preregistration for Intra-abdominal infections (Combination therapy, Complicated) in USA (IV), prior to February 2025
  • 07 Feb 2025 Registered for Intra-abdominal infections (Combination therapy, Complicated) in USA (IV)
  • 07 Feb 2025 AbbVie announces its intention to launch EMBLAVEO for Intra-abdominal infections (Combination therapy, Complicated) in USA in the third quarter of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top